How do you advise patients on duration of first line maintenance PARPi and the potential risk of MDS or AML?   

Is MDS/AML risk increased with longer duration of therapy? Does your approach differ for patients who are BRCA+/HRD vs wild type/HRP?

Answer from: at Academic Institution

Answer from: Medical Oncologist at Academic Institution